Systematic review and meta-analysis shows death education improves end-of-life care competence in nurses
Death education programs boost nurse confidence in end-of-life care skills
This systematic review and meta-analysis evaluated death education programs for nurses and nursing students. The analysis included 1,142 par…
A review of 13 studies found that death education programs significantly improved nurses confidence in providing end-of-life care, though ch…
FDA Approves Tofidence (tocilizumab-bavi) for Multiple Inflammatory Conditions and COVID-19
FDA approves new biosimilar drug Tofidence for arthritis and COVID-19.
FDA approved Tofidence (tocilizumab-bavi), an IL-6 receptor antagonist, for rheumatoid arthritis, giant cell arteritis, polyarticular juveni…
The FDA approved Tofidence (tocilizumab-bavi), a biosimilar to tocilizumab, for rheumatoid arthritis, giant cell arteritis, juvenile arthrit…
Case report of cefotaxime treatment for peritoneal dialysis-related peritonitis in an elderly patient
Elderly patient on peritoneal dialysis recovered after cefotaxime treatment
This case report describes the treatment of an elderly patient with peritoneal dialysis-related peritonitis using cefotaxime. The patient re…
An elderly patient with peritoneal dialysis-related peritonitis recovered after receiving cefotaxime treatment in a case report.
Case Report and Review of Recurrent Dysplasia Epiphysealis Hemimelica After Surgery
One patient's surgery failed at three months, showing how age and incomplete removal cause recurrence
This case report and literature review describes a patient with recurrent Dysplasia Epiphysealis Hemimelica 3 months after surgical interven…
A single patient saw the condition return within three months after surgery, bringing back pain and stiffness. This case highlights the need…
Core set domains capture SLE treatment response in 89.5% of cases at week 52
Core set domains capture most lupus disease activity in a global trial
This phase III randomized controlled trial evaluated subjects with Systemic Lupus Erythematosus across a global setting. The study compared …
A global trial found that a core set of domains captured most lupus disease activity without missing important patient responses.
Meta-analysis finds hydroxychloroquine does not reduce most pregnancy complications in SLE
Hydroxychloroquine May Lower Risk of Fetal Growth Restriction in Lupus Pregnancy
This meta-analysis of observational studies and RCTs assessed hydroxychloroquine use in pregnant women with SLE. It found no significant red…
In lupus pregnancies, hydroxychloroquine was linked to lower risks of fetal growth restriction and gestational diabetes, but not other compl…
Systematic review and meta-analysis of Wuqinxi for knee osteoarthritis joint function
Wuqinxi exercise improves knee function and muscle strength in osteoarthritis patients
This systematic review and meta-analysis evaluated Wuqinxi (WQX) in patients with knee osteoarthritis. The analysis pooled data from 809 par…
A review of eight hundred and nine patients found that Wuqinxi exercise significantly improved knee function and muscle strength compared to…
Systematic review of acupuncture for sepsis-associated acute gastrointestinal injury
Acupuncture helped some sick patients feel better but did not save more lives in this review
This systematic review and meta-analysis synthesized evidence on adjunctive acupuncture for sepsis-associated acute gastrointestinal injury …
This review looked at acupuncture for very sick people with stomach problems caused by sepsis. While it helped lower inflammation and improv…
FDA Approves Rinvoq Lq (upadacitinib) for Polyarticular Juvenile Idiopathic Arthritis
FDA approves new oral drug Rinvoq Lq for children with arthritis.
The FDA approved Rinvoq Lq (upadacitinib) for patients 2 years and older with active polyarticular juvenile idiopathic arthritis after inade…
The FDA approved Rinvoq Lq (upadacitinib) for children ages 2 and older with active polyarticular juvenile idiopathic arthritis (pJIA) who d…
FDA Approves Tyenne (tocilizumab-aazg) for Multiple Inflammatory Conditions
FDA approves new biosimilar drug Tyenne for arthritis and other conditions.
The FDA approved Tyenne (tocilizumab-aazg), an IL-6 receptor antagonist, for rheumatoid arthritis, giant cell arteritis, polyarticular and s…
The FDA approved Tyenne, a biosimilar to tocilizumab, for several inflammatory conditions including rheumatoid arthritis and giant cell arte…
FDA Approves Tyenne (tocilizumab-aazg) for Multiple Indications Including RA and COVID-19
FDA approves new biosimilar drug Tyenne for arthritis and COVID-19
The FDA approved Tyenne (tocilizumab-aazg), a biosimilar to tocilizumab, for multiple indications including rheumatoid arthritis, giant cell…
The FDA has approved Tyenne, a biosimilar to tocilizumab, for several inflammatory conditions and COVID-19. It treats rheumatoid arthritis, …
Four weekly text messages for 6 months showed modest CVD risk factor improvements in Swedish hypertension patients
Text messages helped sedentary patients control hypertension risk factors
This randomized controlled trial involved 401 Swedish primary care patients with hypertension. Participants received four health-promoting t…
Sending four weekly health-promoting text messages improved heart risk control for sedentary patients with high blood pressure over six mont…